Eternity in Medical Information -- Medisurf
Search | Web Directory, News, Variable useful Information, PubMed In Medine, All
Category Select :
Items 101 ~ 120 of 25572, Page 6 of 1280
101. Medtronic Co-Founder Earl Bakken Passes Away at Age 94
(GLOBE NEWSWIRE via COMTEX) --DUBLIN - October 21, 2018 - Medtronic plc (NYSE:MDT) announced today that its co-founder, Earl E. Bakken, passed away peacefully on October 21, 2018 at his home on Kiholo Bay on the Big Island of Hawaii. He was 94 years old.
10/21/2018 Medtronic
102. Giant study links DNA variants to same-sex behavior
A study of hundreds of thousands of people uncovered four genetic variants that were more common in people who reported at least one instance of same-sex sexual behavior.
10/20/2018 Science: Biology, Brain & Behavior News by Michael Price
103. Merck"s KEYTRUDA® (pembrolizumab) Showed a Complete Response Rate of Nearly 40 Percent in Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Standard of Care
First-Time Data for KEYTRUDA in NMIBC from Phase 2 KEYNOTE-057 Trial to be Presented at ESMO 2018 Congress
10/20/2018 MERCK
104. First Presentation of Early Data for Merck’s Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 Congress
New Clinical Findings Involving STING Agonist as Monotherapy and in Combination with an Anti-PD-1 Therapy
10/20/2018 MERCK
105. Abbott''s HeartMate 3 Heart Pump Now FDA Approved for Advanced Heart Failure Patients Not Eligible for a Heart Transplant
ABBOTT PARK, Ill., Oct. 19, 2018 /PRNewswire/ Abbott (NYSE: ABT) announced today that the HeartMate 3™ Left Ventricular Assist Device (LVAD) has received U.S. Food and Drug Administration (FDA) approval as a destination therapy for people living with advanced heart failure. With the approval, physicians can now offer the HeartMate 3 system to patients not eligible for a transplant who will live with their device for the rest of their lives.
10/19/2018 Abbott
106. Virus detectives test whole-body scans in search of HIV hiding places
To prevent the virus from rebounding after drug therapy, researchers must first map where it lurks in the body.
10/19/2018 Nature News by Sara Reardon
107. Hospitals could save $25.4B annually in supply chain costs, study finds
The study of 2,300 U.S. hospitals found facilities could save an average of 17.7 percent or $11 million annually per hospital on supply chain products and related operations, processes and procedures if they performed in the top 25 percent of hospitals nationwide for supply chain budget efficiency.
10/19/2018 Becker's Hospital Review by Kelly Gooch
108. Nation"s Medical Specialists Demand Immediate End to Prior Authorization Abuse
Physicians, patients and Congress agree: Medicare Advantage plans must stop needless delays in medically necessary care
10/19/2018 American Academy of Ophthalmology
109. AMA unveils playbook to speed digital health adoption
Wearables and other devices generate a flood of patient information. This new resource helps physicians put that data to use in their practices.
10/19/2018 American Medical Association (AMA) News by Sara Berg
110. ''A new day for chemistry'': Molecular CT scan could dramatically speed drug discovery
The new approach builds on a technique called electron diffraction, which sends an electron beam through a crystal and, as in x-ray crystallography, determines structure from diffraction patterns.
10/19/2018 Scinece: Chemistry News by Robert F. Service
111. Group Purchasing Organizations, Health Care Costs, and Drug Shortages
GPOs can serve a valuable role in the purchasing of drugs and medical supplies; however, hospitals should consider several factors when selecting a GPO and the products that the GPO offers.
10/18/2018 JAMA. Published online October 18, 2018. doi:10.1001/jama.2018.13604
112. A revolutionary treatment for allergies to peanuts and other foods is going mainstream but do the benefits outweigh the risks?
Physicians with deep roots in food allergy immunotherapy hope those new to it tread carefully.
10/18/2018 Science: Biology, Health, People & Events News by Jennifer Couzin-Frankel
113. Abortion Reversal?- Legislating without Evidence
We should all be concerned when politicians recommend treatment options over the advice of medical professionals.
10/18/2018 N Engl J Med 2018; 379:1491-1493
114. Merck"s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma
KEYTRUDA is First Anti-PD-1 Therapy in Combination to Improve Both OS and PFS in Advanced or Metastatic RCC, the Most Common Type of Kidney Cancer Pivotal Phase 3 KEYNOTE-426 Trial Met Both Primary Endpoints; Data to be Filed with Global Regulatory Authorities
10/18/2018 MERCK
115. The Supreme Court''s Crisis Pregnancy Center Case ?Implications for Health Law
After the Supreme Court''s decision in National Institute of Family and Life Advocates v. Becerra (NIFLA) in late June 2018, the status of such laws is an open question.
10/18/2018 N Engl J Med 2018; 379:1489-1491
116. Don''t fall for these 3 myths about AI, machine learning
Get the straight scoop from a Johns Hopkins expert developing health care solutions powered by AI and machine learning.
10/17/2018 American Medical Association (AMA) News by Sara Berg
117. Lassa Fever in Nigeria in 2018
During 2018, an unusual increase in Lassa fever cases occurred in Nigeria, raising concern among national and international public health agencies. We analyzed 220 Lassa virus genomes from infected patients, including 129 from the 2017?018 transmission season, to understand the viral populations underpinning the increase.
10/17/2018 N Engl J Med 2018;
118. Fall 2018 Unified Agenda: FDA's New Regulatory Work to Advance Health and Safety
Today, the federal government published the Fall 2018 Unified Agenda.
10/17/2018 U.S. Food and Drug Administration (FDA)
119. Abbott Reports Third-Quarter 2018 Results
ABBOTT PARK, Ill., Oct. 17, 2018 /PRNewswire/ Abbott (NYSE: ABT)?today announced financial results for the third quarter ended Sept. 30, 2018.
10/17/2018 Abbott
120. New Study Shows Abbott''s Novel Diagnostic Test has the Potential to Demonstrate Gold Standard Accuracy and Speed, Which Could Help Rule Out Heart Attacks Earlier at the Point of Care
ABBOTT PARK, Ill., Oct. 17, 2018 /PRNewswire/ For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart attack.
10/17/2018 Abbott
   
1 2 3 4 5 6 7 8 9 10
 
경기도 성남시 분당구 구미동 25-1 엘레강스 프라자 ㈜ 메디서프 | Tel : 031-896-0930 | 사업자 등록번호 : 212-81-47247
통신판매신호번호 : 경기 성남 2007-712 | 대표이사 한상욱